Real-world treatment patterns and outcomes among metastatic cutaneous melanoma patients treated with ipilimumab
P Mohr, P Ascierto, A Arance, G McArthur, A Hernaez, P Kaskel, R Shinde, K Stevinson
Journal of the European Academy of Dermatology and Venereology | WILEY | Published : 2018
BACKGROUND: There is a scarcity of real-world data on treatment patterns and outcomes among advanced melanoma patients treated with immunotherapies including ipilimumab, an anti-CTLA-4 antibody approved since 2011. OBJECTIVE: To evaluate ipilimumab and postipilimumab treatment patterns and outcomes among patients with advanced melanoma in Australia, Germany, Italy and Spain, following regulatory approval. METHODS: Retrospective multicentre, multinational, observational chart review study. Data were extracted from the start of ipilimumab therapy until the end of at least 40 weeks of follow-up, or death. RESULTS: Data from 371 patients (Australia, 103; Germany, 152; Italy, 76; Spain, 40) were ..View full abstract
Funding for this research was provided by Merck & Co., Inc., Kenilworth, NJ.